Research programme: autoimmune disorder therapeutics - Polyneuron Pharmaceuticals

Drug Profile

Research programme: autoimmune disorder therapeutics - Polyneuron Pharmaceuticals

Alternative Names: PN 1007; PN 1018

Latest Information Update: 22 Jul 2016

Price : $50

At a glance

  • Originator Polyneuron Pharmaceuticals
  • Class Glycopeptides; Immunotherapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Motor neuron disease; Peripheral nervous system diseases

Most Recent Events

  • 15 Jul 2016 Preclinical trials in Peripheral nervous system diseases and Motor neuron disease in Switzerland (unspecified route) (Polyneuron Pharmaceuticals pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top